Pharma
sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

See Latest Articles
(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Sepracor Announces Patent Interference Proceedings (and Schedule) Against Wyeth for Claims Related to O-desmethylvenlafaxine Succinate (Marketed as PRISTIQ(R))
Sepracor, 04/20/09

Sepracor Inc. announced that the Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office has combined three patent interferences into a single interference between Sepracor and Wyeth and set a date for oral arguments. The interference seeks to determine the priority of inventorship of claims directed to racemic O-desmethylvenlafaxine succinate. Wyeth markets racemic ODMV succinate in the U.S. under the brand name PRISTIQ(R) for the treatment of major depressive disorder in adults.

Today in Marketing/Media/ROI...keeping you current

Alcon to Enter Surgical Glaucoma Market by Acquiring Optonol
Alcon, 12/15/09

Hospira Buys Infection Control Vendor
HealthDataManagement, 12/11/09

Mediware Makes Two Buys
HealthDataManagement, 12/10/09

 See all of Marketing/Media/ROI

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address